Current perspectives on immunotherapy for colorectal cancer

Drugs of Today

Volumn 36, Issue 4, 2000, Pages 201-213

  Maxwell Armstrong, C A ^a   Scholefield, J H ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CYTOKINE; DIPHTHERIA TOXOID; DNA VACCINE; HEAT SHOCK PROTEIN; IDIOTYPIC ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 2; LEVAMISOLE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; PLACEBO; POLYCLONAL ANTIBODY; PROTEIN P53; TUMOR ANTIGEN; VIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY RESPONSE; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; HUMAN; NONHUMAN; REVIEW; TUMOR IMMUNOLOGY; VACCINATION;

EID: 0034028610     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2000.36.4.570199     Document Type: Review

References (125)

1. OPCS. Mortality statistics by cause: England and Wales 1992. Series DH2, Number 20. HMSO: London 1995.
2. On the state of the public health. The Annual Report of the Chief Medical Officer of the Department of Health. HMSO: London 1991.
3. Maxwell-Armstrong, C.A., Durrant, L.G., Scholefield, J.H. Colorectal cancer vaccines. Br J Surg 1998, 85: 149-54.
4. Maxwell-Armstrong, C.A., Durrant, L.G., Scholefield, J.H. Immune treatment for colorectal cancer. Recent Adv Surg 1998, 21: 97-111.
5. Maxwell-Armstrong, C.A., Durrant, L.G., Scholefield, J.H. The immune-therapy of colorectal cancer. Am J Surg 1999, 177: 344-8.
6. Robins, R.A. T cell responses at the host:tumour interface. Biochem Biophys Acta 1986, 856: 289-305.
7. Lennox, E.S., Sikora, K. Definition of human tumour antigens. In: Monoclonal Antibodies in Clinical Medicine. McMichael, ?, Fabre, ? (Eds.). Academic Press: London 1982.
8. Hodge, J.W. Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol Immunother 1996, 43: 127-32.
9. Gimmi, C., Morrison, B.W., Mainprice, B.A. et al. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med 1996, 2: 1367-70.
10. Falk, R.E., MacGregor, A.B., Landi, S. et al. Immunostimulation with intraperitoneally administered bacille Calmette Guerin for advanced malignant tumors of the gastrointestinal tract. Surg Gynecol Obstet 1976, 142: 363-8.
11. Mavligit, G.K., Burgess, M.A., Burton Seibert, G. et al. Prolongation of postoperative disease-free interval and survival in human colorectal cancer by BCG, or BCG plus 5-fluorouracil. Lancet 1976, i: 871-6.
12. Hoover, H.C. Jr., Brandhorst, J.S., Peters, L.C. et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993, 11: 390-9.
13. Richards, F. 2d, Muss, B.B., Cooper, R. et al. Chemotherapy versus chemoimmunotherapy in advanced adenocarcinoma of the colon and rectum: A prospective randomized study. Cancer 1979, 43: 91-6.
14. Smith, K.A. Interleukin-2: Inception, impact and implications. Science 1988, 240: 1169-76.
15. Rosenberg, S.A., Lotze, M.I.T., Yang, J.C. Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989, 210: 474-85.
16. Brivio, F., Lissoni, P., Alden, G. et al. Preoperative IL-2 subcutaneous immunotherapy may prolong survival time in advanced colorectal cancer patients. Oncology 1996, 53: 263-8.
17. Triozzi, P.L., Kim, J.A., Martin, E.W. et al. Phase I trial of escalating doses of interleukin-1beta in combination with a fixed dose of interleukin-2. J Clin Oncol 1995, 13: 482-9.
18. O'Hara, R.J., Drew, P.J., Lee, P.W.R. et al. JASS score, immune suppression and interleukin-12 production: A functional link. Br J Surg 1997, 94: 713.
19. Yamaue, K., Tanimura, H. Clinical application of IL-2 and IL-4 for cancer biotherapy. Biotherapy 1996, 10: 1147-53.
20. Laurie, J.A., Moertel, C.G., Fleming, T.R. et al. Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989, 7: 1447-56.
21. Arnand, J.P., Buyse, K., Nordhinga, B. Results of an EORTC double-blind randomised clinical trial. Br J Surg 1959, 76: 284-9.
22. Chlebowski, R.T., Nystrom, S., Reynolds, R. et al. Long-term survival following levamisole or placebo or adjuvant treatment of colorectal cancer: A Western Cancer Study Group Trial. Oncology 1988, 45: 141-7.
23. Moertel, C.G., Fleming, T.R., MacDonald, J.S. et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990, 322: 352-8.
24. Buzzi, S., Baccini, C., Rubboli, D. et al. Immunological effects of a boiled diphtheria toxoid on high risk cancer patients. Proc Am Assoc Cancer Res 1997, 38: 397.
25. Rosenberg, S.A. The development of new immunotherapies for the treatment of cancer using interleukin-2. Ann Surg 1988, 208: 121-35.
26. Lafreniere, R., Rosenberg, S.A. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. Cancer Res 1985, 45: 3735-41.
27. Rosenberg, S.A., Lotze, M.T., Muul, L.M. et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987, 316: 889-97.
28. Freedman, R.S., Edwards, C.L., Kavanagh, J.J. et al. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: A pilot trial. J Immunother Emphasis Tumor Immunol 1994, 16: 198-210.
29. Thiounn, N., Mathiot, C., Flam, T. et al. CD4 TIL (tumor infiltrating lymphocytes) induce complete response in patients treated with IL-2 (interleukin-2). Preliminary study. J Urol (Paris) 1994, 100: 185-8.
30. Griffith, K.D., Read, E.J., Carrasquillo, U.A. et al. In vivo distribution of adoptively transferred indium-111-labelled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst 1989, 81: 1709-17.
31. Fagerberg, J., Hjelm, A.L., Ragnhammar, P. et al. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res 1995, 55: 1824-27.
32. Ragnhammar, P., Fagerberg, J., Frodin, J.E. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma - Long lasting complete remissions can be induced. Int J Cancer 1993, 53: 751-8.
33. Bungard, S., Flieger, D., Schweitzer, S. et al. The combination of interleukin-2 and interferon α effectively augments the antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2 against the colorectal carcinoma cell line HT29. Cancer Immunol Immunother 1998, 46: 213-20.
34. Shetye, J., Ragnhammar, P., Lilfefors, M. et al. Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1998, 4: 1921-9.
35. Wadler, S. The role of immunotherapy in colorectal cancer. Semin Oncol 1991, 18: 27-38.
36. Riethmuller, G., Holz, E., Schlimok, G. et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998, 16: 1788-94.
37. Pimm, M.V., Perkins, A.C., Armitage, N.C. et al. The characteristics of blood-borne radiolabels and the effect of anti-mouse IgG antibodies on localization of radiolabeled monoclonal antibody in cancer patients. J Nucl Med 1985, 26: 1011-23.
38. Begent, R.H.J., Verhaar, M.J., Chester, K.A. et al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 1996, 2: 979-84.
39. Tuttle, T.M. Oncogene products represent potential targets of tumor vaccines. Cancer Immunol Immunother 1996, 43: 135-41.
40. Lane, D.P., Crawford, L.V. Tantigen is bound to a host protein in SV40-transformed cells. Nature 1979, 278: 261-3.
41. Linzer, D.I., Levine, A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979, 17: 43-52.
42. Hall, P.A., Meek, D., Lane, D.P. p53 - Integrating the complexity. J Pathol 1996, 180: 1-5.
43. Levine, A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88: 323-31.
44. Hollstein, K., Sidransky, D., Vogelstein, B. et al. p53 mutations in human cancers. Science 1991, 253: 49-53.
45. Kawakami, Y., Eliyahu, S., Jennings, C. et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating lymphocytes associated with in vivo tumor regression. J Immunol 1995, 154: 3961-8.
46. Remvikos, Y., Tominaga, O., Hammel, P. et al. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 1992, 66: 758-64.
47. Hamelin, R., Laurent-Puig, P., Olschwang, S. et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994, 106: 42-8.
48. Bosari, S., Viale, G., Bossi, P. et al. Cytoplasmic accumulation of p53 protein: An independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 1994, 86: 681-7.
49. + cytotoxic T cells. Cancer Res 1993, 53: 3257-61.
50. Noguchi, Y., Richards, E.C., Chen, Y.T. et al. Influence of interleukin-12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 1995, 92: 2219-23.
51. Gabrilovich, D.I., Cunningham, H.T., Carbone, D.P. IL-12 and mutant p53 peptidepulsed dendritic cells for the specific immunotherapy of cancer. J Immunother Emphasis Tumor Immunol 1996, 19: 414-8.
52. Ropke, K., Regner, K., Claesson, M.H. T cell mediated cytotoxicty against p53 protein derived peptides in bulk and limiting dilution cultures of healthy donors. Scand J Immunol 1995, 42: 98-103.
53. Bertholet, S., Iggo, R., Corradin, G. Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides. Eur J Immunol 1997, 27: 798-801.
54. Vierboom, M.P.M., Nijman, H.W., Offringa, R. et al. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 1997, 5: 695-704.
55. Bos, J.L. Ras oncogenes in human cancer: A review. Cancer Res 1989, 49: 4682-9.
56. Peace, D.J., Smith, J.W., Chen, W. Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide. J Exp Med 1994, 179: 473-9.
57. Peace, D.J., Smith, J.W., Disis, M.L. et al. Induction of T cells specific for the mutated segment of oncogenic p21 ras protein by immunization in vivo with the oncogenic protein. J Immunother 1993, 14: 110-4.
58. Skipper, J., Stauss, H.J. Identification of two cytotoxic T-lymphocytes recognizing epitopes in the ras protein. J Exp Med 1993, 177: 1493-8.
59. Gjertsen, M.K., Bakka, A., Breivik, J. et al. Vaccination with mutant ras peptides and induction of T cell responsiveness in pancreatic cancer patients carrying the corresponding ras mutation. Lancet 1995, 346: 1399-400.
60. + T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Cell Immunol 1997, 182: 137-51.
61. Morse, M.A., Deng, Y., Coleman, D. et al. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999, 5: 1331-8.
62. Nisonoff, A., Lamoyi, E. Implications of the presence of an internal image of the antigen anti-idiotypic antibodies: Possible applications to vaccine production. Clin Immunol Immunopathol 1981, 21: 397-406.
63. Roitt, I.M., Cooke, A., Male, D.K. et al. Idiotypic networks and their possible exploitation for manipulation of the immune response. Lancet 1981, i: 1041-5.
64. Lindemann, J., Jerne, N.K. Speculations on Ids and homobodies. Ann Immunol 1974, 124: 171-84.
65. Raychaudhuri, S. Anti-idiotype antibodies: An alternative approach to tumor immunotherapy. Indian J Exp Biol 1989, 27: 671-80.
66. Herlyn, D., Lubeck, M., Sears, H. et al. Specific detection of anti-idiotypic immune responses in cancer patients treated with murine monoclonal antibody. J Immunol Methods 1985, 85: 27-35.
67. Herlyn, D., Benden, A., Kane, M. et al. Anti-idiotype cancer vaccines: Preclinical and clinical studies. In Vivo 1991, 5: 615-24.
68. Maruyama, H., Benden, A., Li, W. et al. Monoclonal anti-idiotypic antibody functionally mimics the human gastrointestinal carcinoma epitope GA733. Int J Cancer 1996, 65: 547-53.
69. Samonigg, H., Wilders-Truschnig, M., Loibner, H. et al. Immune response to tumor antigens in a patient with colorectal cancer after immunization with anti-idiotype antibody. Clin Immunol Immunopathol 1992, 65: 271-7.
70. Austin, E.B., Robins, R.A., Durrant, L.G. et al. Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36. Immunology 1989, 67: 525-30.
71. Spendlove, I., Li, L., Carmichael, J. et al. Decay accelerating factor (CD55): A target for cancer vaccines. Cancer Res 1999, 59: 2282-6.
72. Austin, E.B., Robins, R.A., Baldwin, R.W. et al. Induction of delayed hypersensitivity to human tumor cells with a human monoclonal anti-idiotypic antibody. J Natl Cancer Inst 1991, 83: 1245-8.
73. Robins, R.A., Denton, G.W.L., Hardcastle, J.D. et al. Antitumor immune response and interleukin-2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody. Cancer Res 1991, 51: 5425-9.
74. Denton, G.W.L., Durrant, L.G., Hardcastle, J.D. et al. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int J Cancer 1994, 57: 10-4.
75. Durrant, L.G., Maxwell-Armstrong, C.A., Buckley, T.J.D. et al. Double blind randomized trial of 105AD7 in advanced colorectal cancer. Br J Surg 1997, 84: Abst 1579.
76. Maxwell-Armstrong, C.A., Buckley, T.J.D., Durrant, L.G. et al. The anti-idiotypic monoclonal antibody 105AD7 increases lymphocytic infiltration of primary colorectal tumours. Br J Surg 1996, 83: Abst 1650.
77. Maxwell-Armstrong, C.A., Durrant, L.G., Robins, R.A. et al. Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105AD7. Gut 1999, 45: 593-8.
78. Durrant, L.G., Buckley, T.J.D., Denton, G.W.L. et al. Enhanced cell-mediated tumor killing in patients immunized with human monoclonal anti-idiotypic antibody 105AD7. Cancer Res 1994, 54: 4837-40.
79. Durrant, L.G., Maxwell-Armstrong, C.A., Buckley, D. et al. A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, that mimics CD55. Clin Cancer Res 1999, in press.
80. Buckley, T.J.D., Robins, R.A., Durrant, L.G. Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7 delays tumor growth by stimulating anti-tumor T-cell responses. Hum Antibodies Hybridomas 1995, 6: 68-72.
81. Foon, K.A., Chakraborty, M., John, W.J. et al. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J Clin Invest 1995, 96: 334-42.
82. Foon, K.A., John, W.J., Chakraborty, M. et al. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin Cancer Res 1997, 3: 1267-76.
83. Itkowitz, S., Kjeldsen, T., Friera, A. Expression of Tn, sialosyl Tn and T antigen in human pancreas. Gastroenterology 1991, 100: 1691-700.
84. Jerome, K.R., Bu, D., Finn, O.J. Expression of tumor-associated epitopes on Epstein-Barr virus-immortalized B-cells and Burkitt's lymphomas transfected with epithelial mucin complementary DNA. Cancer Res 1992, 52: 5985-90.
85. Jerome, K.R., Barnd, D.L., Bendt, K.M. et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991, 51: 2908-16.
86. Barnd, D.L., Lan, M., Metzger, R. et al. Specific major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989, 86: 7159-63.
87. Kotera, Y., Fontenot, J.D., Pecher, G. et al. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994, 54: 2856-60.
88. Gourevitch, M.M., von Mensdorff-Pouilly, S., Litnivov, S.V. et al. Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br J Cancer 1995, 72: 934-8.
89. Nakamura, H., Hinoda, Y., Nakagawa, N. et al. Detection of circulating anti-MUC-1 mucin core protein antibodies in patients with colorectal cancer. J Gastroenterol 1998, 33: 354-61.
90. Pecher, G., Finn, O.J. Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells. Proc Natl Acad Sci USA 1996, 93: 1600-704.
91. Goydos, J.S., Elder, E., Whiteside, T.L. et al. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 1996, 63: 298-304.
92. + lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother 1996, 42: 303-9.
93. Ulmer, J.B., Donnelly, J.J., Parker, S.E. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259: 1745-9.
94. Wolff, J.A., Malone, R.W., Williams, P. et al. Direct gene transfer into mouse muscle in vivo. Science 1990, 247: 1465-8.
95. Conry, R.K., LoBuglio, A.F., Loechel, F. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther 1995, 2: 59-65.
96. Conry, R.M., Saleh, M.N., Schlom, J. et al. Human immune response to carcinoembryonic antigen tumor vaccines. J Immunother 1995, 18: 137-41.
97. Syrengelas, A.D., Chen, T.T., Levy, R. DNA immunization induces protective immunity against B cell lymphoma. Nat Med 1996, 2: 1038-41.
98. Irvine, K.R., Rao, J.B., Rosenberg, S.A. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 1996, 156: 238-45.
99. Conry, R.M., LoBuglio, A.F., Curiel, D.T. Phase la trial of a polynucleotide anti-tumor immunization to human carcinoembryonic antigen in patients with metastatic colorectal cancer. Hum Gene Ther 1996, 7: 755-72.
100. Conry, R.M., Widera, G., LoBuglio, A.F. Selected strategies to augment polynucleotide immunization. Gene Ther 1996, 3: 67-74.
101. Conry, R.M., LoBuglio, A.F., Curiel, D.T. Polynucleotide-mediated immunization therapy of cancer. Semin Oncol 1996, 23: 135-147.
102. Conry, R.M., LoBuglio, A.K., Kantor, J. et al. Immune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res 1994, 54: 1164-8.
103. Ciernik, I.F., Berzofsky, J.A., Carbone, D.P. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J Immunol 1996, 156: 2369-75.
104. Udono, H., Srivastava, P.K. Heat shock protein 70 associated peptides elicit specific cancer immunity. J Exp Med 1993, 178: 1391-6.
105. Li, Z., Srivastava, P.K. Tumor rejection antigen gp96/grp94 is an ATPase: Implications for protein folding and antigen presentation. EMBO J 1993, 12: 3143-51.
106. Srivastava, P.K., DeLeo, A.B., Old, L.J. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci USA 1986, 83: 3407-11.
107. Ullrich, S.J., Robinson, E.A., Law, L.W. et al. A mouse tumor-specific transplantation antigen is a heat shock related protein. Proc Natl Acad Sci USA 1986, 83: 3121-5.
108. Palladino, M.A., Srivastava, P.K., Oettgen, H.F. et al. Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas. Cancer Res 1987, 47: 5074-9.
109. Janetzki, S., Blachere, N.E., Srivastava, P.K. Generation of tumor-specific cytotoxic T lymphocytes and memory T cells by immunization with tumor-derived heat shock protein gp96. J Immunother 1998, 21: 269-76.
110. Tamura, Y., Peng, P., Liu, K. et al. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997, 278: 117-20.
111. Kantor, J., Irvine, K., Abrams, S. et al. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res 1992, 52: 6917-25.
112. Kantor, J., Abrams, S., Irvine, K. et al. Specific immunotherapy using a recombinant vaccinia virus expressing human carcinoembryonic antigen. Ann NY Acad Sci 1993, 690: 370-3.
113. Kaufman, H., Schlom, J., Kantor, J. A recombinant vaccinia virus expressing human carcinoembryonic antigen. Int J Cancer 1991, 48: 900-7.
114. Wright, P., Zheng, C., Moyana, T. et al. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis (TNF)-α induces significant tumor regression. Cancer Gene Ther 1998, 5: 371-9.
115. Li, W., Berencsi, K., Basak, S. et al. Human colorectal cancer (CRC) antigen CO17-1A/GA 733 encoded by adenovirus inhibits growth of established CRC cells in mice. J Immunol 1997, 159: 763-9.
116. Tsang, K.Y., Zaremba, S., Nieroda, C.A. et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995, 87: 982-90.
117. Fujiwara, T., Cai, D.W., Georges, R.N. et al. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994, 86: 1458-62.
118. Mukhopadhyay, T., Tainsky, M., Cavender, A.C. et al. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 1991, 51: 1744-8.
119. Roth, J.A., Nguyen, D., Lawrence, D.D. et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996, 9: 985-91.
120. Spitz, F.R., Nguyen, D., Skibber, J.M. et al. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res 1996, 16: 3415-22.
121. Ogawa, N., Fujiwara, T., Kagawa, S. et al. Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. Int J Cancer 1997, 73: 367-70.
122. Bischoff, J.R., Kirn, D.K., Williams, A. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274: 373-6.
123. Heise, C., Sampson-Johannes, A., Williams, A. et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997, 3: 639-45.
124. Steele, R.J.C., Thompson, A.K., Hall, P.A. et al. The p53 tumour suppressor gene. Br J Surg 1998, 85: 1460-7.
125. Sivanandham, M., Shaw, P., Bemik, S.F. et al. Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice. Cancer Immunol Immunother 1998, 46: 261-7.